Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Squamous Cell Carcinoma of Head and Neck 13Oropharyngeal Neoplasms 11Lung Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Mouth Neoplasms 8Laryngeal Neoplasms 8Carcinoma 8Urinary Bladder Neoplasms 6Nasopharyngeal Carcinoma 6Hypopharyngeal Neoplasms 6Pancreatic Neoplasms 5Mesothelioma, Malignant 5Uterine Cervical Neoplasms 4Ovarian Neoplasms 4Medulloblastoma 4Ganglioneuroblastoma 4Gallbladder Neoplasms 4Neuroblastoma 3Lymphoid Interstitial Pneumonia 3Cholangiocarcinoma 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Paranasal Sinus Neoplasms 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1

Interventions

Cyclophosphamide 13Specimen Handling 9cabozantinib 8X-Rays 8Magnetic Resonance Spectroscopy 8fludarabine 7Phantoms, Imaging 7Biopsy 7Temozolomide 6Methotrexate 6Zoledronic Acid 5Gemcitabine 5Doxorubicin 5regorafenib 4pembrolizumab 4Vincristine 4Nuclear Medicine Department, Hospital 4Nivolumab 4Ifosfamide 4Cisplatin 4olaparib 3irinotecan sucrosofate 3fludarabine phosphate 3dinutuximab 3Surveys and Questionnaires 3Irinotecan 3Etoposide 3ulixertinib 2tipifarnib 2tazemetostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × 1,2-diaminocyclohexaneplatinum II citrate × 1 year × Clear all
NCT05691478 2026-06-03

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

National Cancer Institute (NCI)

Phase 2/3 Recruiting
1,122 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡